This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 115/13/1729    most recent CIRCULATIONAHA.106.672873v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Isenburg, J. C. Articles by Vyavahare, N. R. Search for Related Content PubMed PubMed Citation Articles by Isenburg, J. C. Articles by Vyavahare, N. R. Related Collections Animal models of human disease Other Treatment CV surgery: aortic and vascular disease Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage Other Vascular biology

(Circulation. 2007;115:1729-1737.)
© 2007 American Heart Association, Inc.

Cardiovascular Surgery

Elastin Stabilization for Treatment of Abdominal Aortic Aneurysms

Jason C. Isenburg, PhD^*; Dan T. Simionescu, PhD^*; Barry C. Starcher, PhD; Narendra R. Vyavahare, PhD

From the Department of Bioengineering (J.C.I., D.T.S., N.R.V.) Clemson University, Clemson, SC, and Department of Biochemistry, University of Texas Health Center, Tyler (B.C.S.).

Correspondence to Narendra R. Vyavahare, PhD, Cardiovascular Implant Research Laboratory, Department of Bioengineering, Clemson University, 501 Rhodes Engineering Research Center, Clemson, SC 29634. E-mail narenv{at}clemson.edu

Received November 3, 2006; accepted January 26, 2007.

Background— Maintaining the integrity of arterial elastin is vital for the prevention of abdominal aortic aneurysm (AAA) development. We hypothesized that in vivo stabilization of aortic elastin with pentagalloyl glucose (PGG), an elastin-binding polyphenol, would interfere with AAA development.

Methods and Results— Safety and efficacy of PGG treatment were first tested in vitro using cytotoxicity, elastin stability, and PGG-elastin interaction assays. For in vivo studies, the efficacy of PGG was evaluated within a well-established AAA model in rats on the basis of CaCl₂-mediated aortic injury. With this model, PGG was delivered periadventitially at 2 separate time points during the course of AAA development; aortic diameter, elastin integrity, and other pathological aspects were monitored and evaluated in PGG-treated aortas compared with saline-treated control aortas. Our results show that a one-time periadventitial delivery of noncytotoxic levels of PGG inhibits elastin degeneration, attenuates aneurysmal expansion, and hinders AAA development in rats without interfering with the pathogenic mechanisms typical of this model, namely inflammation, calcification, and high metalloproteinase activities. PGG binds specifically to arterial elastin and, in doing so, preserves the integrity of elastic lamellae despite the presence of high levels of proteinases derived from inflammatory cells.

Conclusions— Periadventitial administration of PGG hinders the development of AAA in a clinically relevant animal model. Stabilization of aortic elastin in aneurysm-prone arterial segments offers great potential toward the development of safe and effective therapies for AAAs.

---

 

CLINICAL PERSPECTIVE